Neck

Shrujal Baxi, MD, MPH, Joins Iterative Scopes As Chief Medical Officer

Retrieved on: 
Thursday, September 1, 2022
Health, Medical Devices, Technology, Health Technology, General Health, Artificial Intelligence, Pharmaceutical, University, Public health, CEO, Technology, Cancer, Inflammatory bowel disease, AI, University of Illinois School of Information Sciences, Disease, Head, Memorial Sloan Kettering Cancer Center, Bowel obstruction, MIT, Tecmar, Neck, GI, Health information management, Science, IBD, Multimedia, Faculty, Exocrine gland, Illinois College, MBBS, Human, Health policy, Scope, Gastrointestinal disease, RWD, Gastroenterology, Colorectal cancer, MPH, Oncology, CMO, Pharmaceutical industry, Medicine, Medical imaging, New York University, MD

Iterative Scopes , a pioneer in precision-medicine technologies for gastroenterology, announced today that Shrujal Baxi, MD, MPH, has joined its leadership team as Chief Medical Officer.

Key Points: 
  • Iterative Scopes , a pioneer in precision-medicine technologies for gastroenterology, announced today that Shrujal Baxi, MD, MPH, has joined its leadership team as Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220901005134/en/
    Shrujal Baxi, MD, MPH, joins Iterative Scopes as Chief Medical Officer.
  • (Photo: Business Wire)
    Having a stellar scientific, medical, and regulatory affairs team is critical to Iterative Scopes work, and we're very excited to have Dr. Baxi leading these groups, says Jonathan Ng, MBBS, founder and CEO of Iterative Scopes.
  • Iterative Scopes is advancing the science of gastroenterology and facilitating clinical trials in IBD, and this should be shared and celebrated.

SkinMedica® Launches Firm & Tone Lotion for Body

Retrieved on: 
Wednesday, August 31, 2022
Cream, AbbVie, Technology, NYSE, Research, ABBV, Skin, Senior, Science, Yale School of Medicine, Extracellular matrix, Ligamentous laxity, The Firm (brand), Face, Neck, Patient, Cosmetics, Body, Caffeine

IRVINE, Calif., Aug. 31, 2022 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of SkinMedica® Firm & Tone Lotion for Body, the first product from the professional-grade skincare line formulated to prevent and address visible signs of body skin aging for a toned look.1 It is clinically proven to diminish the look of crepey skin, address uneven skin texture, improve the appearance of body skin firmness and tone, and improve the look of sagging skin.1

Key Points: 
  • "Environmental factors, such as sun exposure and pollutants, and intrinsic factors, including changes in fat distribution and muscle tone, take a toll on the body.2 SkinMedica Firm & Tone Lotion for Body is a luxurious formula rooted in science that delivers transformative results."
  • SkinMedica Firm & Tone Lotion for Body contains carefully curated ingredients including Green Microalgae and Shitake Mushroom Extracts, Lemon Balm Extract, Coffea Arabica Seed Oil, Caffeine, Hydrolyzed Rice Protein, Japanese Parsley, Paradisi (Grapefruit Peel) Oil, and Ginger Root Extract.
  • In addition to adding SkinMedica Firm & Tone lotion to my patients' overall body care regimen as a standalone, patients can also use the product following body contouring procedures."
  • In a head-to-head clinical study1 where the products were used twice a day, investigators assessed the following improvements at weeks 4, 8, and 12:
    On both the upper arms and thighs for skin smoothness, skin tone evenness, crepiness, body skin firmness, and body texture
    Firm & Tone Lotion showed significant visible improvements vs. a leading professional-grade topical body for body skin crepiness, texture, skin tone evenness, and smoothness.1

Kent Douglas McIntire, DO, FAOCO, is recognized by Continental Who's Who

Retrieved on: 
Wednesday, August 31, 2022
American Osteopathic Board of Ophthalmology and Otolaryngology, ENT, Mentorship, Continental, American Academy, View, Nazarene University, Time, Outline of health sciences, Skin cancer, Kaleida Health, Neck, Freeman Health System, Osteopathic medicine in the United States, Education, American Academy of Otolaryngology–Head and Neck Surgery, Multimedia, American Osteopathic Association, McIntire, MD, Buffalo, Hospital, Fellow, Kansas City University, Ear, Face, Sleep apnea, DO, Dentistry, Otorhinolaryngology, Science, New Guinea, Ophthalmology, Biology, Head, Osteopathy

JOPLIN, Mo., Aug. 30, 2022 /PRNewswire/ -- Kent Douglas McIntire, DO, FAOCO, is being recognized by Continental Who's Who as a Distinguished Surgeon for his exemplary career in Otolaryngology and in acknowledgment of his accomplishments with Freeman Ear, Nose, and Throat Center.

Key Points: 
  • JOPLIN, Mo., Aug. 30, 2022 /PRNewswire/ -- Kent Douglas McIntire, DO, FAOCO, is being recognized by Continental Who's Who as a Distinguished Surgeon for his exemplary career in Otolaryngology and in acknowledgment of his accomplishments with Freeman Ear, Nose, and Throat Center.
  • Freeman Ear, Nose & Throat Center offers the latest state-of-the-art equipment and instrumentation.
  • In pursuit of his education, Dr. McIntire obtained a Bachelor of Science in Biology from Mid-American Nazarene University.
  • To further his training, Dr. McIntire completed a Fellowship in Head and Neck Surgery at Buffalo General Hospital.

Ronald G. Presswood, DDS is recognized by Continental Who's Who

Retrieved on: 
Monday, August 29, 2022
University, Private practice, Dental surgery, CQR, Continental, Research, DDS, Obstructive sleep apnea, Dentistry, Physician, Neck, Organization, Pain scale, Royal Canadian Dental Corps, USS Essex, Royal Hospital Chelsea, Dentures, RGP, Snoring, National Exchange Club, Dentist, United States Department of the Navy, Dental school, Love, Patient, Dental

HOUSTON, Aug. 29, 2022 /PRNewswire/ -- Ronald G. Presswood, DDS, is being recognized by Continental Who's Who as a Trusted Dentist for his achievements in the Dental field and in acknowledgment of his work in private practice.

Key Points: 
  • HOUSTON, Aug. 29, 2022 /PRNewswire/ -- Ronald G. Presswood, DDS, is being recognized by Continental Who's Who as a Trusted Dentist for his achievements in the Dental field and in acknowledgment of his work in private practice.
  • With over 50 years of experience, Dr. Ronald G. Presswood is a highly-rated dentist practicing in Houston, TX.
  • In addition, he treats patients with debilitating head, neck, and facial pain, which has become his primary focus of practice study and research.
  • Upon returning to the United States in 1968, Dr. Presswood opened his private practice in Houston.

Easy Assembly, UPS Shippable and Ergonomic Design Are Core to BEDGEAR's® New Flex L™ Adjustable Base

Retrieved on: 
Monday, August 29, 2022
Zero, Back pain, Tablet, Bed, Collection, UPS, Head, Temperature, Pressure, Weightlessness, Neck, Flex, Rest, Sleep, Travel, Performance

With its minimalistic, ergonomic design, the Flex L provides an option for consumers who require the essential up and down motion and programmable memory positions.

Key Points: 
  • With its minimalistic, ergonomic design, the Flex L provides an option for consumers who require the essential up and down motion and programmable memory positions.
  • "The Flex L Adjustable Base provides all the necessary mattress adjustments to allow consumers to comfortably use their laptops and tablets, read and respond to emails, write documents, complete spreadsheets, create graphics, edit videos and conduct video conference calls.
  • Equally important, the Flex L can be easily and quickly assembled without tools by an individual in just minutes, and because it is extremely lightweight, it can be delivered via UPS."
  • Starting at $799, the Flex L includes a 10-year limited warranty and is available in Twin XL, Queen, King and Cal King.

Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

Retrieved on: 
Monday, August 29, 2022
RNA interference, Liver cancer, Laser, AES, Metastasis, Scar, RNA, Safety, CEO, Squamous cell carcinoma, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Basal-cell carcinoma, Liver, Food and Drug Administration, Doctor of Philosophy, CR, PSC, Head, Population, Board, Skin, Phase, Infection, Radiation, Food, Injection, Neck, Behzad Razavi, Incidence, Cryosurgery, SCC, NMPA, Lymph, BCC, MD, Sirna, Company, FDA, Therapy, Șaeș, PNP, Cancer, Cholangiocarcinoma, NMSC, Bleeding, Risk, HTS, Face, Clinical trial, Primary sclerosing cholangitis, CCA, Hypertrophic scar, Patient, Pharmaceutical industry

GAITHERSBURG, Md and SUZHOU, China, Aug. 29, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the cohort receiving the 180μg dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response (CR), indicating the promising viability of the treatment. STP705 is a siRNA (small interfering RNA) therapeutic that is composed of two siRNA oligonucleotides, targeting the expression of TGF-β1 and COX-2 mRNA, respectively.

Key Points: 
  • The Company is continuing to explore doses in the ongoing dose escalation study and anticipates a final report in Q1 2023.
  • "Based on the successes of both BCC and isSCC (cutaneous squamous cell carcinoma in situ) clinical studies, Sirnaomics is spearheading the development of the novel polypeptide-based siRNA therapeutics for various types of cancers."
  • Basal cell carcinoma (BCC) is a type of nonmelanoma skin cancer (NMSC) that is associated with exposure to ultraviolet radiation from the sun.
  • STP705 is currently in seven clinical trials for different indications: a Phase IIb for squamous cell carcinoma in situ (isSCC), a Phase II for basal cell carcinoma (BCC), a Phase I/II for keloid scarring, a Phase I/II for hypertrophic scar (HTS), a Phase I/II for facial isSCC, a Phase I for liver cancer (basket), and a Phase I for medical cosmetology treatment.

Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 25, 2022
COVID-19, Technology, Research, Squamous cell carcinoma, Liver, Xi, Risk, Carcinosarcoma, U.S. Securities and Exchange Commission, SCC, 100,000, GLOBE, Company, Investor, PMDA, Prostate cancer, Vii, Alpha Tau Delta, Patient, Neoadjuvant therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Head, Food, SEC, Nasdaq, FDA, Environmental protection, Annual report, Trial of the century, KOL, D, Financial result, GBM, Skin cancer, IDE, Health Canada, D&O, Pancreatic tumor, BCC, Prostate, Private Securities Litigation Reform Act, Marketing, RECIST, Neoplasm, Ministry, XV, Alpha Sigma Tau, Pancreatic cancer, Neck, G&A, Medical device, Medical imaging, Pharmaceutical industry, Renewable energy, Alpha, Tel Aviv University

JERUSALEM, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported second quarter 2022 financial results and provided a corporate update.

Key Points: 
  • The Company expects to treat its first patient in this study later in 2022-
    JERUSALEM, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the Company), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported second quarter 2022 financial results and provided a corporate update.
  • First patient treated in a feasibility study evaluating the Alpha DaRT as a neoadjuvant therapy in patients with prostate cancer.
  • Expecting first patient treated in U.S. multi-center pivotal trial in recurrent cutaneous SCC in the second half of 2022.
  • Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors.

New Range of Derila Pillows Launched

Retrieved on: 
Thursday, August 25, 2022
People, Spine, Shoulder, Man, Head, Temperature, PayPal, Pressure, Policy, Neck, Viscosity, Human, Mastercard, Visa, Neck pain, Woman, Health, Sleep, Online shopping, Lace

Doctors especially addressed the promotion of cervical alignment for optimal sleeping posture when designing the ergonomic contour of the Derila.

Key Points: 
  • Doctors especially addressed the promotion of cervical alignment for optimal sleeping posture when designing the ergonomic contour of the Derila.
  • A new and improved brand of cushion called the Derila Pillow is comprised of memory foam.
  • Choose a Derila Pillow instead of local pillows that may become compressed after a while to lengthen the sleep and increase comfort.
  • Although one of these pillows can cost up to $71.90 per purchase, the official Derila pillow website offers purchases with a discount.

New Range of Derila Pillows Launched

Retrieved on: 
Thursday, August 25, 2022
People, Spine, Shoulder, Man, Head, Temperature, PayPal, Pressure, Policy, Neck, Viscosity, Human, Mastercard, Visa, Neck pain, Woman, Health, Sleep, Online shopping, Lace

Doctors especially addressed the promotion of cervical alignment for optimal sleeping posture when designing the ergonomic contour of the Derila.

Key Points: 
  • Doctors especially addressed the promotion of cervical alignment for optimal sleeping posture when designing the ergonomic contour of the Derila.
  • A new and improved brand of cushion called the Derila Pillow is comprised of memory foam.
  • Choose a Derila Pillow instead of local pillows that may become compressed after a while to lengthen the sleep and increase comfort.
  • Although one of these pillows can cost up to $71.90 per purchase, the official Derila pillow website offers purchases with a discount.

Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congress 2022

Retrieved on: 
Thursday, August 25, 2022
Research, Women, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Consumer, Health, Science, Oncology, Transfer, European Society for Medical Oncology, Ministry, Safety, HPV, Merck Sharp & Dohme Federal Credit Union, Human papillomavirus infection, KOSDAQ, Head, CKD, Judgement, Hope, Cervical cancer, Neck, Data analysis, DNA, International Money Transfers System Leader, Goal, Pembrolizumab, Immunotherapy, Therapy, DART, Oncology, Merck, Congress, Merck & Co., MFDS, Patient, Pharmaceutical industry, Vaccine, Food, Korean

We believe this could offer hope for a new immunotherapy treatment option to patients with recurrent/metastatic end-stage cervical cancer.

Key Points: 
  • We believe this could offer hope for a new immunotherapy treatment option to patients with recurrent/metastatic end-stage cervical cancer.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
  • Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics.
  • Genexine has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value.